LeonaBio (LONA) Cash from Investing Activities (2019 - 2026)
LeonaBio (LONA) reported Cash from Investing Activities of -$15.5 million for Q1 2026, down 111.4% year-over-year from $136.3 million in Q1 2025, and down 6.16% on a QoQ basis from -$14.6 million in Q4 2025.
LeonaBio (LONA) has 8 years of Cash from Investing Activities data on file, last reported at -$15.5 million in Q1 2026.
- Quarterly Cash from Investing Activities fell 111.4% year-over-year to -$15.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.1 million (down 169.93% YoY) and the FY2025 annual result came in at -$15.9 million, down 128.99% from the prior year.
- Cash from Investing Activities slipped to -$15.5 million in Q1 2026 per LONA's latest filing, from -$14.6 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $35.5 million in Q1 2023 and bottomed at -$15.5 million in Q1 2026.
- The 5-year median for Cash from Investing Activities is $13.0 million (2024), against an average of $10.4 million.
- The widest annual swing landed in 2023, when Cash from Investing Activities surged 828.22%; it then sank 420.55% in 2025.
- Tracing LONA's Cash from Investing Activities over 5 years: stood at $24.6 million in 2022, then sank by 74.07% to $6.4 million in 2023, then slumped by 144.0% to -$2.8 million in 2024, then slumped by 420.55% to -$14.6 million in 2025, then fell by 6.16% to -$15.5 million in 2026.
- Per Business Quant, the three latest LONA Cash from Investing Activities figures stand at -$15.5 million (Q1 2026), -$14.6 million (Q4 2025), and $5.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -428.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -25.54 Mn |
| 10 | LeonaBio | 181.52 Mn | 113.84 Mn | - | -15.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.54 Mn |
| Mar 31, 2026 | -15.54 Mn |
| Dec 31, 2025 | -14.64 Mn |
| Dec 31, 2025 | -14.64 Mn |
| Sep 30, 2025 | 5.65 Mn |
| Sep 30, 2025 | 5.65 Mn |
| Jun 30, 2025 | 441,000.00 |
| Jun 30, 2025 | 441,000.00 |
| Mar 31, 2025 | -7.35 Mn |
| Mar 31, 2025 | -7.35 Mn |
| Dec 31, 2024 | -2.81 Mn |
| Dec 31, 2024 | -2.81 Mn |
| Sep 30, 2024 | 18.04 Mn |
| Sep 30, 2024 | 18.04 Mn |
| Jun 30, 2024 | 26.56 Mn |
| Jun 30, 2024 | 26.56 Mn |
| Mar 31, 2024 | 13.04 Mn |
| Mar 31, 2024 | 13.04 Mn |
| Dec 31, 2023 | 6.39 Mn |
| Dec 31, 2023 | 6.39 Mn |
| Sep 30, 2023 | 20.69 Mn |
| Sep 30, 2023 | 20.69 Mn |
| Jun 30, 2023 | 32.49 Mn |
| Jun 30, 2023 | 32.49 Mn |
| Mar 31, 2023 | 35.52 Mn |
| Mar 31, 2023 | 35.52 Mn |
| Dec 31, 2022 | 24.65 Mn |
| Dec 31, 2022 | 24.65 Mn |
| Sep 30, 2022 | 13.63 Mn |
| Sep 30, 2022 | 13.63 Mn |
| Jun 30, 2022 | -4.46 Mn |
| Jun 30, 2022 | -4.46 Mn |
| Mar 31, 2022 | 23.85 Mn |
| Mar 31, 2022 | 23.85 Mn |
| Dec 31, 2021 | 21.37 Mn |
| Dec 31, 2021 | 21.37 Mn |
| Sep 30, 2021 | -14.20 Mn |
| Sep 30, 2021 | -14.20 Mn |
| Jun 30, 2021 | 11.46 Mn |
| Jun 30, 2021 | 11.46 Mn |
| Mar 31, 2021 | -22.71 Mn |
| Mar 31, 2021 | -22.71 Mn |
| Dec 31, 2020 | -115.76 Mn |
| Dec 31, 2020 | -115.76 Mn |
| Sep 30, 2020 | -94.31 Mn |
| Sep 30, 2020 | -94.31 Mn |
| Jun 30, 2020 | 2,000.00 |
| Jun 30, 2020 | 2,000.00 |
| Mar 31, 2020 | 1,000.00 |
| Mar 31, 2020 | 1,000.00 |
| Dec 31, 2019 | 751,000.00 |
| Dec 31, 2019 | 751,000.00 |